Buy Avanafil / Dapoxetine Hydrochloride online in Ireland – fast, discreet & affordable

Developed in the early 2000s, Avanafil is a rapid-onset PDE5 inhibitor used to treat erectile dysfunction; Dapoxetine hydrochloride is a short-acting selective serotonin reuptake inhibitor approved for on-demand relief of premature ejaculation. Together, these agents exemplify distinct pharmacologic approaches to male sexual dysfunction and may appear in combination formulations in some clinical references.

Overview of Avanafil / Dapoxetine Hydrochloride and its drug class

Avanafil exerts its effect by selective inhibition of phosphodiesterase type 5 (PDE5), leading to increased cyclic guanosine monophosphate (cGMP) and augmented penile vasodilation in the presence of sexual stimulation. Dapoxetine hydrochloride acts as a rapid-onset selective serotonin reuptake inhibitor (SSRI) to delay ejaculation by central mechanisms. In combination form, the two agents address two common male sexual disorders: erectile dysfunction and premature ejaculation, using distinct pharmacologic targets.

Pharmacodynamically, Avanafil is associated with rapid onset and a favorable selectivity profile that reduces the likelihood of visual or color-vision disturbances seen with some PDE5 inhibitors. Dapoxetine provides on-demand control of ejaculation with a short half-life, which minimizes prolonged exposure. Clinically, these characteristics support on-demand dosing compatible with patient use around sexual activity.

How it compares to related substances in the same class

Within the PDE5 inhibitor class, Avanafil is distinguished by its relatively rapid onset and higher selectivity for PDE5 over PDE6, which may translate to fewer ocular side effects compared with some peers. Other PDE5 inhibitors (sildenafil, tadalafil, vardenafil) vary in onset, duration, and food interactions, influencing choice based on patient needs and comorbidities. Dapoxetine, as an on-demand SSRI for premature ejaculation, differs from longer-acting antidepressants used off-label for PE and from non-SSRI approaches.

When used for premature ejaculation, Dapoxetine is designed for short exposure around anticipated ejaculation, whereas other SSRIs require chronic dosing with delayed onset of therapeutic effect. The combination conceptually aligns two distinct pharmacologic strategies: rapid erectile facilitation and rapid ejaculation delay, each with separate safety and interaction profiles that must be evaluated together in clinical practice.

Therapeutic uses

The primary indication for Avanafil is treatment of adult men with erectile dysfunction, to improve erectile function in response to sexual stimulation. Dapoxetine hydrochloride is indicated for on-demand treatment of premature ejaculation in adult men, to increase intravaginal ejaculatory latency time and improve control. In a combination product, the intended population includes men presenting with both ED and PE, allowing a dual mechanism to address two coexisting disorders.

Use should be guided by clinical judgment, patient preferences, and contraindications. Both agents require consideration of cardiovascular status, concomitant medications, and potential drug interactions. Counseling should address onset times, possible side effects, and the need to avoid use with nitrates or incompatible therapy.

Key differences from similar medications

The table below highlights contrasts among Avanafil, sildenafil, and tadalafil, focusing on onset, duration, and practical considerations relevant to combination or individual therapy.

Safety profile summary

As with PDE5 inhibitors, Avanafil carries risks of hypotension when combined with nitrates or certain antihypertensives, and is contraindicated in patients with known hypersensitivity to the drug. Dapoxetine carries potential for dizziness, nausea, and somnolence; caution is advised in patients with a history of syncope or significant liver impairment. The combination of these agents requires careful assessment of cardiovascular status, liver function, and potential drug interactions, particularly with other serotonergic medications and CYP3A4 inhibitors or inducers.